Abstract:
Oral solid dosage forms feature high manufacturing efficiency, favourable drug stability and convenient storage and transportation, and serve as the predominant dosage forms for first-line clinical therapy. Owing to immature metabolic capacity and swallowing function in paediatric populations, conventional oral solid dosage forms are mainly indicated for patients aged 6 years and above. Represented by multiparticulate systems, orally disintegrating tablets, minitablets and nanoformulations, novel oral solid micro-nano formulations have substantially extended the applicable age down to the infant stage, and can meet most oral medication demands of paediatric patients. In recent years, considerable research advances have been achieved in the preparation technologies, taste-masking processes and clinical applications of the above-mentioned micro-nano formulations, which also reveals the future development direction of paediatric oral solid micro-nano formulations.